TICKERNERD
Menu
PLYXHealthcare · Biotechnology

PLYX Stock Forecast: Polaryx Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.01
+1.01% on the day

The 4 Wall Street analysts covering Polaryx Therapeutics, Inc. hold a median 12-month price target of $7 — +248.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$95.2M
Ticker Nerd rank
15 / 100
Median analyst target
$7.00
Analysts covering
4
Revenue$0.0
Operating income−$1.4M
Net income−$1.4M
Free cash flow−$1.4M
Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.0%
1M
−8.6%
From high
−94.3%
From low
+7.5%
$2
$35
Range since 2 Feb 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

PLYX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Polaryx Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
75
Value
64
Accruals
43
Revisions
33
Issuance
33
Growth
25
Quality
18
Volatility
3
Momentum
2

Size (75): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PLYX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLYX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 2 Feb 2026Adjusted close, US dollars
$0$10$20$30$40Apr 26Jul 26PLYXHigh $10.00Median $7.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $6.00Median $7.00High $10.00

The green dot is the last close — the median target sits +248.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026Raymond JamesInitiatesStrong Buy$6.00
27 July 2026LUCID CAPITAL MARKETSInitiatesBuy—
27 July 2026LUCID CAPITAL MARKETSInitiatesBuy$7.00
9 July 2026HC Wainwright & Co.InitiatesBuy$7.00
9 July 2026HC Wainwright & Co.InitiatesBuy—
27 Feb 2026Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLYX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PLYX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

PLYX vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Apr 26Jul 26PLYXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PLYX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Polaryx Therapeutics, Inc. (PLYX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.6×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
9.2×

Cheaper than 10% of US stocks

EV / EBITDA
−13.3×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−96.6%

Higher than 14% of US stocks

Return on assets
−42.5%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Polaryx Therapeutics, Inc. (PLYX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Polaryx Therapeutics, Inc. has a market value of $95.2M and an enterprise value of $88.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$6.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$5.8M.

  • Shares outstanding: 49.8M.

  • Trailing P/E: −10.6×; forward P/E: −7.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Polaryx Therapeutics, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

PLYX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PLYXPolaryx Therapeutics, Inc.$95.2M
15
GUTSFractyl Health, Inc.$101.5M
31
COYACoya Therapeutics, Inc.$102.7M
58
PYPDPolyPid Ltd.$104.6M
52
PMVPPMV Pharmaceuticals, Inc.$105.7M
78
ATRAAtara Biotherapeutics, Inc.$94.2M
68
CGTXCognition Therapeutics, Inc.$93.5M
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Polaryx Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PLYX news & analysis

Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer

GlobeNewsWire · 1 Sept 2026positive

Polaryx Therapeutics, Inc. announced the appointment of Dr. Will Charlton as Chief Medical Officer, according to GlobeNewsWire. Dr. Charlton brings over 15 years of experience in rare disease and pediatric drug development, including prior chief medical officer and clinical development roles.

Why it matters — PLYX watchers would care because adding an executive with deep rare-disease and pediatric drug development expertise could strengthen the company's clinical leadership as it advances its programs.

Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial

GlobeNewsWire · 25 Aug 2026positive

Polaryx Therapeutics provided an operational readiness update for SOTERIA, its Phase 2 basket trial evaluating lead candidate PLX-200 across four rare pediatric lysosomal storage disorders. The company remains focused on initiating the trial in the fourth quarter of 2026, following FDA authorization, CRO engagement, and Fast Track Designation.

Why it matters — A PLYX watcher would care because the update signals continued advancement of the company's lead candidate toward the start of its Phase 2 basket trial.

FAQ

Frequently asked questions about PLYX stock

What is the PLYX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Polaryx Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PLYX stock a buy right now?

Of the 4 analysts covering Polaryx Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Polaryx Therapeutics, Inc. 15 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PLYX?

As at 12 Sept 2026, Polaryx Therapeutics, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (75 of 100).

Will PLYX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +248.3% from the last close, and Ticker Nerd's factor model ranks Polaryx Therapeutics, Inc. 15 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PLYX stock forecast for 2030?

No analyst covering Polaryx Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLYX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $10 over the next 12 months.

What does Polaryx Therapeutics, Inc. do?

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare pediatric lysosomal storage disorders.

What is the latest news on PLYX?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer". Polaryx Therapeutics, Inc. announced the appointment of Dr. Will Charlton as Chief Medical Officer, according to GlobeNewsWire. Dr. Charlton brings over 15 years of experience in rare disease and pediatric drug development, including prior chief medical officer and clinical development roles.

Company

About Polaryx Therapeutics, Inc.

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare pediatric lysosomal storage disorders. Polaryx Therapeutics works on small molecule and gene therapy programs designed to address the underlying biology of severe inherited conditions, including neuronal ceroid lipofuscinoses, Krabbe disease, Tay-Sachs and Sandhoff diseases, and Niemann-Pick disease types A and B. Its current portfolio emphasizes patient-friendly treatment approaches, including orally available small molecules and a gene therapy candidate, supporting its role in the rare disease drug development market. Headquartered in Paramus, New Jersey, and founded in 2014, Polaryx Therapeutics is positioned as a specialized biotechnology company addressing areas of high unmet medical need.

CEO Mr. Alex Yang J.D., L.L.M. · 2 employees · United States · https://polaryx.com